Vaccines and the Infectious Diseases They Prevent

Image representing the teeth of a bat with IMOVAX RABIES and IMOGRAM RABIES-HT writen below

Indications and Usage

IMOGAM Rabies–HT Immune Globulin is indicated for post-exposure treatment of individuals who have been exposed to rabies (confirmed or suspected), particularly severe exposure, with one exception: persons who have been previously vaccinated with IMOVAX Rabies vaccine in a pre- or post-exposure treatment series should receive only IMOVAX Rabies vaccine^1,2

IMOGAM Rabies–HT Immune Globulin should be used (at the first dose of post-exposure treatment) with IMOVAX Rabies vaccine^1,2
- The recommended dose is 20 IU/kg (0.133 mL/kg) or 9 IU/lb (0.06 mL/LB) of body weight^1,3

If possible, the full dose of IMOGAM Rabies–HT Immune Globulin should be infiltrated around the wound(s); any remaining volume should be given as an intramuscular injection at a site distant from where the IMOVAX Rabies vaccine will be given^1,2

IMOGAM Rabies-HT Immune Globulin should not be administered in the same syringe as IMOVAX Rabies vaccine^1,2

Treatment with IMOGAM Rabies–HT Immune Globulin should NOT be given in repeated doses once post-exposure treatment has been started because it may interfere with the immune response to IMOVAX Rabies vaccine^1,2

As with any vaccine, vaccination with a rabies vaccine or rabies immune globulin may not protect 100% of individuals

Find out more about rabies post-exposure vaccination NOW!

View full Prescribing Information for IMOGAM Rabies–HT Immune Globulin .

References: 1. IMOGAM Rabies–HT Prescribing Information, December 2005. 2. Centers for Disease Control and Prevention (CDC). Human rabies prevention—United States, 1999: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 1999;48:1-21. 3. Loofbourow JC, Cabasso VJ, Roby RE, Anuskiewicz W. Rabies immune globulin (human): clinical trials dose determination. JAMA. 1971;217:1825-1831.

IMOVAX® Rabies

Indication

IMOVAX Rabies vaccine is indicated for active, pre- and post-exposure immunization against rabies.

Safety Information
The most common local and systemic adverse reactions to IMOVAX Rabies vaccine may include injection site pain, erythema, and swelling; headache, nausea, and muscle aches. Other adverse reactions may occur. Once initiated for post-exposure treatment rabies vaccination should not be interrupted or discontinued because of mild local or systemic adverse reactions. Usually such reactions can be successfully managed with anti-inflammatory and antipyretic agents. Vaccination with IMOVAX Rabies vaccine may not protect all individuals.

Before administering IMOVAX Rabies vaccine, please see accompanying full Prescribing Information.

IMOGAM® Rabies–HT

Indication
IMOGAM Rabies-HT immune globulin is given for passive immunization of individuals suspected of exposure to rabies.

Safety Information
Side effects to the IMOGAM Rabies-HT immune globulin include injection site tenderness, pain, and muscle soreness or stiffness. Other side effects may occur. IMOGAM Rabies-HT immune globulin should not be given in repeated doses once vaccine treatment has begun. IMOGAM Rabies-HT immune globulin is made from components of human blood and, therefore, this vaccine may carry a risk of transmitting infectious material, although careful selection of donors and extensive testing are intended to minimize this risk. Treatment with a rabies immune globulin may not protect all individuals.

For more information about IMOGAM Rabies-HT immune globulin, talk to your health-care professional.

Last modified: 5/2/08